...
机译:激素受体阳性,HER2阴性转移性乳腺癌的内分泌治疗:延伸内分泌敏感性
Department of Oncology Azienda Ospedaliero Universitaria di Ferrara-Arcispedale Sant’Anna;
Breast Centre Department of Oncology AUSL Toscana Centro-Prato;
Department of Oncology Medical Oncology Unit ARNAS Garibaldi;
Depertment of Oncology Medical OncologyandBreast Unit “Antonio Perrino” Hospital;
University of PaduaandIstituto Oncologico Veneto;
Department of Breast and Thoracic Oncology National Cancer Institute Fondazione “G.Pascale”;
Department of OncologyandHematology Medical Oncology 2 IRCCS Ospedale Policlinico San Martino;
Department of Oncology IRCCS Sacro Cuore-Don Calabria Hospital;
Department of Clinical MedicineandSurgery University of Naples “Federico II”;
Medical Oncology Unit Sant’Andrea Hospital of RomeandIDI-IRCCS;
Medical Oncology “Santa Chiara” Hospital;
Direzione Day Hospital Oncologico Multidisciplinare Istituto di Candiolo FPO-IRCCS;
Oncology B Unit Sapienza University of Rome;
Department of OncologyandHematology Medical Oncology 2 IRCCS Ospedale Policlinico San Martino;
Department of Medicine University of Udine;
Department of Medical Oncology Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII;
abemaciclib; CDK4/6 inhibitor; endocrine therapy; fulvestrant; metastatic breast cancer; palbociclib; ribociclib;
机译:激素受体阳性,HER2阴性转移性乳腺癌的内分泌治疗:延伸内分泌敏感性
机译:预测敏感性对内分泌治疗(套装)在Neoadjuvant化疗之前II-III激素受体阳性和HER2阴性(HR + / HER2-)乳腺癌的乳腺癌
机译:针对患有激素受体阳性,HER2阴性转移性乳腺癌的绝经后患者的一线内分泌治疗:系统审查和荟萃分析
机译:基于社会认知理论的监测药物依从性的框架应用于乳腺癌幸存者的内分泌治疗
机译:内分泌非依赖性乳腺癌的内分泌治疗新方法
机译:CDK4 / 6抑制剂的比较整体存活加上内分泌治疗与内分泌治疗单独用于激素受体阳性HER2阴性转移性乳腺癌
机译:内分泌治疗与蛋白质受体阳性,HER2阴性,转移性乳腺癌的绝经后妇女化疗:系统审查和网络元分析